Two New Takes on Making a Type of Targeted Cancer Therapy Even Better

Why It Matters

Bispecific and epitope‑focused ADCs promise higher specificity and lower toxicity, potentially reshaping precision oncology for hard‑to‑treat solid cancers.

Key Takeaways

• Sidewinder’s bispecific ADCs bind two tumor‑expressed receptors for enhanced delivery
• Stipple’s platform maps tumor‑only epitopes to avoid healthy‑cell toxicity
• Sidewinder total financing now $162 million; Stipple raised $100 million
• Both companies target squamous cell, head‑and‑neck, and gastrointestinal cancers
• First‑in‑human studies slated for 2027, accelerating ADC pipeline timelines

Pulse Analysis

The resurgence of antibody‑drug conjugates reflects a broader industry shift toward precision oncology, where the therapeutic index hinges on accurate tumor targeting. Sidewinder Therapeutics is leveraging bispecific antibodies—a technology already proven in oncology—to create ADCs that latch onto a co‑complex of two surface proteins. By pairing a driver receptor with an internalizing partner, the payload is more likely to be internalized by cancer cells, reducing off‑target exposure and potentially lowering the incidence of dose‑limiting side effects. This design could set a new benchmark for ADC efficacy, especially in solid tumors that have historically been challenging for antibody‑based therapies.

Stipple Bio’s approach tackles the same problem from a different angle, using high‑resolution epitope mapping to discover surface markers that are truly tumor‑restricted. Its STP‑100 candidate exemplifies a next‑generation ADC that binds only to these exclusive epitopes, further sharpening selectivity. The $100 million Series A round, led by a16z Bio+Health and RA Capital, underscores investor confidence in epitope‑centric strategies as a pathway to differentiate in a crowded ADC market. By minimizing collateral damage to normal tissue, Stipple aims to improve patient tolerability and broaden the therapeutic window for potent cytotoxins.

Both firms plan to initiate human trials in 2027, a timeline that aligns with the industry’s push to bring more sophisticated ADCs to clinic faster. Their combined $262 million infusion of capital signals robust market appetite for innovations that can overcome the limitations of first‑generation ADCs. If successful, these technologies could expand treatment options for patients with squamous cell carcinomas of the lung, head and neck, and gastrointestinal tract—areas where current options are limited and unmet medical need remains high. Investors and clinicians alike will watch the upcoming data closely, as they could redefine standards for targeted cancer therapy.